16D0 Dicker, Adam P. - Thomas Jefferson University - Thomas Jefferson University

Adam P. Dicker, MD, PhD, FASTRO

Contact Dr. Dicker

111 South 11th Street
Room G-301, Bodine Center
Philadelphia, PA 19107

(215) 955-6700
(215) 503-0013 fax

Most Recent Peer-reviewed Publications

  1. Genomic classifier identifies men with adverse pathology after radical prostatectomy who benefit from adjuvant radiation therapy
  2. Radiation therapy after radical prostatectomy for prostate cancer: Evaluation of complications and influence of radiation timing on outcomes in a large, population-based cohort
  3. Novel actions of next-generation taxanes benefit advanced stages of prostate cancer
  4. American society of clinical oncology policy statement update: The critical role of phase I trials in cancer research and treatment
  5. Current Clinical Trials Testing Combinations of Immunotherapy and Radiation
  6. Assessing adverse events of postprostatectomy radiation therapy for prostate cancer: Evaluation of outcomes in the regione Emilia-Romagna, Italy
  7. African-American race is a predictor of seminal vesicle invasion after radical prostatectomy
  8. Adjuvant versus salvage radiation therapy for prostate cancer patients with adverse pathologic features: Comparative analysis of long-term outcomes
  9. African American men with low-grade prostate cancer have increased disease recurrence after prostatectomy compared with Caucasian men
  10. A tissue biomarker -based model that identi fies patients with a high risk of distant metastasis and differential survival by length of androgen deprivation therapy in RTOG protocol 92-02
  11. Adjuvant radiation for node-positive disease after prostatectomy: More good news, but who will listen?
  12. Radiation protection of the gastrointestinal tract and growth inhibition of prostate cancer xenografts by a single compound
  13. The retinoblastoma tumor suppressor modulates DNA repair and radioresponsiveness
  14. AAPM and GEC-ESTRO guidelines for image-guided robotic brachytherapy: Report of Task Group 192
  15. The lag time in initiating clinical testing of new drugs in combination with radiation therapy, a significant barrier to progress?
  16. Genomic prostate cancer classifier predicts biochemical failure and metastases in patients after postoperative radiation therapy
  17. The KRAS-variant and miRNA expression in RTOG endometrial cancer clinical trials 9708 and 9905
  18. High dose rate brachytherapy boost for prostate cancer: A systematic review
  19. Treatment-related complications of radiation therapy after radical prostatectomy: comparative effectiveness of intensity-modulated versus conformal radiation therapy
  20. Expanding the use of monoclonal antibody therapy of cancer by using ionising radiation to upregulate antibody targets